Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.
Open Access
- 1 February 1986
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 163 (2) , 347-368
- https://doi.org/10.1084/jem.163.2.347
Abstract
We report a novel colony assay for B-lineage progenitor cells in acute lymphoblastic leukemia (ALL). The primary plating efficiency of blast progenitors freshly obtained from common B-lineage ALL patients varied between 0.09 and 2.63%. Morphological, cytochemical, and immunological analyses of cells from day 7 colonies provided the evidence that they are B-lineage lymphoblasts. Immunological marker analyses of cultured blasts using BA-2 (anti-CD9), BA-3 (anti-CD10), BA-1 (anti-CD24), and B43 mAb have allowed us to define two distinct immunological groups. The first group had BA-2+, BA-3+, BA-1+, B43+ marker profiles, consistent with the phenotype of uncultured bone marrow blasts. The second group differed in that the cells in the blast colonies were BA-3 (anti-CD10)-negative, although many of the cells in the bulk population were BA-3+ before culture. Blasts from both groups were able to proliferate and form secondary colonies when recultured. A pan-B immunotoxin was synthesized by linking B43, a human B cell-specific mAb, to pokeweed antiviral protein (PAP). This study showed that B43-PAP can effectively eradicate leukemic progenitor cells freshly obtained from patients with common B-lineage ALL. B43-PAP eliminated greater than 99.96% of blast progenitors under conditions in which only minimal inhibition of normal bone marrow progenitor cells (CFU-GM, CFU-E, CFU-MK, CFU-GEMM) was observed. Our results establish that the surface determinant recognized by B43 is expressed on B-lineage progenitor cells in ALL, and that these cells are sensitive to PAP at the ribosomal level. To our knowledge, B43-PAP is the first IT to prove effective against common B-lineage ALL cells.This publication has 37 references indexed in Scilit:
- Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4- hydroperoxycyclophosphamide to purge tumor cellsBlood, 1985
- AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN 2ND OR SUBSEQUENT REMISSION - RESULTS OF BONE-MARROW TREATED WITH MONOCLONAL-ANTIBODIES BA-1, BA-2, AND BA-3 PLUS COMPLEMENT1985
- Ex vivo elimination of lymphoblastic leukemia cells from human marrow by mafosfamidLeukemia Research, 1985
- In Vitro Cytodestruction of Leukemic Cells in Human Bone Marrow Using a Cocktail of Monoclonal AntibodiesPublished by Springer Nature ,1983
- CLINICAL USEFULNESS OF MONOCLONAL- ANTIBODY PHENOTYPING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIAThe Lancet, 1982
- Radioimmunoassay of ricin A- and B-chains applied to samples of ricin A-chain prepared by chromatofocusing and by DEAE Bio-Gel ABiochimica et Biophysica Acta (BBA) - General Subjects, 1982
- Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin.The Journal of Experimental Medicine, 1982
- P-24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody.The Journal of Experimental Medicine, 1981
- Protection and rescue of ribosomes from the action of ricin A chainBiochemistry, 1979
- Cytochemical profiles in acute lymphoblastic leukemiaJournal of Pediatric Hematology/Oncology, 1979